ligand


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

li·gand

 (lī′gənd, lĭg′ənd)
n.
An ion, molecule, or molecular group that binds to another chemical entity to form a larger complex.

[From Latin ligandus, gerundive of ligāre, to bind; see ligate.]

ligand

(ˈlɪɡənd; ˈlaɪ-)
n
(Chemistry) chem an atom, molecule, radical, or ion forming a complex with a central atom
[C20: from Latin ligandum, gerund of ligāre to bind]

li•gand

(ˈlaɪ gənd, ˈlɪg ənd)

n.
1. a molecule, as an antibody, hormone, or drug, that binds to a receptor.
2. a molecule, ion, or atom that is bonded to the central metal atom of a coordination compound.
[1945–50; < Latin ligandus, ger. of ligāre to bind, tie]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.ligand - a substance (an atom or molecule or radical or ion) that forms a complex around a central atom
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
Translations
Ligand
ligand
References in periodicals archive ?
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), San Diego, has submitted a regulatory application to market its anti-cancer medicine ONZAR(TM) (denileukin diftitox) in the European Union for the treatment of cutaneous T-cell lymphoma (CTCL) patients.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that its stockholders approved all the matters proposed in the Company's recent proxy statement, including the approval of the sale of AVINZA and related assets to King Pharmaceuticals, Inc.
Instead, the tissues appear to produce a molecule, known as Fas ligand, that kills immune cells approaching with destructive intent.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that a special meeting of Ligand's stockholders will be held on February 12, 2007 to vote on approval of the sale of AVINZA and related assets to King Pharmaceuticals, Inc.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") announced today that the Company is initiating Phase I clinical trials of LGD 4665, an oral, small molecule drug that mimics the activity of thrombopoietin (TPO), a growth factor that promotes growth and production of blood platelets.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") today announced that, in connection with the previously announced redemption of its 6% convertible subordinated notes due November 2007, holders of all of the outstanding notes converted their notes into shares of Ligand common stock prior to the November 29, 2006 redemption date.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") will hold a conference call to discuss third quarter 2006 financial results and provide an update on recent events on Wednesday, November 15, 2006, at 11:00 a.
Which companies are developing innovative solutions for computational ligand design?
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") announced today that it has signed a definitive agreement to sell its corporate headquarters building/land and two adjacent undeveloped parcels of land in Torrey Pines Science Center to Slough Estates USA Inc.
This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") today announced that the Board of Directors of Ligand has renewed the stockholder rights plan, which was originally adopted and has been in place since September 1996, and which expired on September 13, 2006, through the adoption of a new 2006 Stockholder Rights Plan (the "2006 Rights Plan").
I, thus, look forward to working with Ligand's experienced board and dedicated employees to help the 'new' Ligand restructure its business model to generate maximum shareholder value.

Full browser ?